Blair William & CO Biomarin Pharmaceutical Inc Transaction History

Blair William & CO

$32.2 Billion
Q1 2025

A detailed history of Blair William & CO transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Blair William & CO holds 4,800 shares of BMRN stock, worth $278,928. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,800

Previous 32,342 85.16%

Holding current value

$278,928

Previous $2.13 Million 84.05%

% of portfolio

0.0%

Previous 0.01%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 09, 2025	SELL	$61.25 - $72.83 $1.69 Million - $2.01 Million	-27,542 Reduced 85.16%	4,800 $339,000
Q4 2024 Feb 12, 2025	SELL	$61.93 - $70.49 $134,635 - $153,245	-2,174 Reduced 6.3%	32,342 $2.13 Million
Q3 2024 Nov 12, 2024	SELL	$69.02 - $93.84 $159,988 - $217,521	-2,318 Reduced 6.29%	34,516 $2.43 Million
Q2 2024 Aug 12, 2024	SELL	$74.43 - $92.22 $70,931 - $87,885	-953 Reduced 2.52%	36,834 $3.03 Million
Q1 2024 May 09, 2024	BUY	$83.81 - $99.0 $73,585 - $86,922	878 Added 2.38%	37,787 $3.3 Million
Q4 2023 Feb 12, 2024	SELL	$76.22 - $98.51 $37,347 - $48,269	-490 Reduced 1.31%	36,909 $3.56 Million
Q3 2023 Nov 09, 2023	BUY	$85.07 - $94.48 $46,958 - $52,152	552 Added 1.5%	37,399 $3.31 Million
Q2 2023 Aug 11, 2023	BUY	$86.68 - $100.3 $25,917 - $29,989	299 Added 0.82%	36,847 $3.19 Million
Q1 2023 May 12, 2023	SELL	$87.74 - $117.27 $325,515 - $435,071	-3,710 Reduced 9.22%	36,548 $3.55 Million
Q4 2022 Feb 10, 2023	SELL	$80.93 - $108.63 $3,237 - $4,345	-40 Reduced 0.1%	40,258 $4.17 Million
Q3 2022 Nov 09, 2022	SELL	$82.16 - $96.94 $207,618 - $244,967	-2,527 Reduced 5.9%	40,298 $3.42 Million
Q2 2022 Aug 10, 2022	BUY	$71.48 - $86.85 $118,299 - $143,736	1,655 Added 4.02%	42,825 $3.55 Million
Q1 2022 May 13, 2022	BUY	$74.28 - $92.69 $41,522 - $51,813	559 Added 1.38%	41,170 $3.17 Million
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $217,239 - $277,062	-3,029 Reduced 6.94%	40,611 $3.59 Million
Q3 2021 Nov 12, 2021	SELL	$74.77 - $85.47 $140,193 - $160,256	-1,875 Reduced 4.12%	43,640 $3.37 Million
Q2 2021 Aug 12, 2021	SELL	$75.51 - $84.79 $101,938 - $114,466	-1,350 Reduced 2.88%	45,515 $3.8 Million
Q1 2021 May 13, 2021	SELL	$74.73 - $90.69 $1.47 Million - $1.78 Million	-19,669 Reduced 29.56%	46,865 $3.54 Million
Q4 2020 Feb 09, 2021	SELL	$72.61 - $90.2 $797,112 - $990,215	-10,978 Reduced 14.16%	66,534 $5.83 Million
Q3 2020 Nov 06, 2020	SELL	$71.87 - $131.03 $858,846 - $1.57 Million	-11,950 Reduced 13.36%	77,512 $5.9 Million
Q2 2020 Aug 12, 2020	BUY	$79.55 - $124.22 $396,397 - $618,988	4,983 Added 5.9%	89,462 $11 Million
Q1 2020 May 11, 2020	BUY	$71.37 - $96.85 $307,604 - $417,423	4,310 Added 5.38%	84,479 $7.14 Million
Q4 2019 Feb 13, 2020	BUY	$64.27 - $86.37 $172,115 - $231,298	2,678 Added 3.46%	80,169 $6.78 Million
Q3 2019 Nov 12, 2019	SELL	$67.4 - $85.11 $713,429 - $900,889	-10,585 Reduced 12.02%	77,491 $5.22 Million
Q2 2019 Aug 13, 2019	BUY	$80.35 - $93.9 $368,565 - $430,719	4,587 Added 5.49%	88,076 $7.54 Million
Q1 2019 May 14, 2019	BUY	$84.2 - $98.62 $338,484 - $396,452	4,020 Added 5.06%	83,489 $7.42 Million
Q4 2018 Feb 14, 2019	BUY	$80.14 - $106.07 $11,299 - $14,955	141 Added 0.18%	79,469 $6.77 Million
Q3 2018 Nov 13, 2018	SELL	$93.92 - $105.72 $19,253 - $21,672	-205 Reduced 0.26%	79,328 $7.69 Million
Q2 2018 Aug 13, 2018	SELL	$76.01 - $99.03 $338,624 - $441,178	-4,455 Reduced 5.3%	79,533 $7.49 Million
Q1 2018 May 15, 2018	SELL	$77.67 - $92.63 $763,107 - $910,089	-9,825 Reduced 10.47%	83,988 $6.81 Million
Q4 2017 Feb 14, 2018	SELL	$80.76 - $95.13 $116,132 - $136,796	-1,438 Reduced 1.51%	93,813 $8.37 Million
Q3 2017 Nov 13, 2017	BUY	$80.6 - $94.95 $7.68 Million - $9.04 Million	95,251	95,251 $8.87 Million

Others Institutions Holding BMRN

# of Institutions

668

Shares Held

184M

Call Options Held

1.24M

Put Options Held

957K

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $10.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Account